寡转移性前列腺癌患者的当前治疗模式与临床结局:一项针对性文献综述
本文针对寡转移性前列腺癌(omPC),检索MEDLINE和Embase及灰色文献,纳入105篇出版物,总结其流行病学、疾病定义、死亡/生存结局及治疗特征。omPC定义随影像技术和转移灶数目/位置而异,多数研究定义为≤5个转移灶;流行病学数据有限;同时性较异时性omPC的死亡率和总生存倾向更差,无进展生存一般更长但长时点更接近;治疗模式异质导致结局多样;需开展采用现代影像技术的临床试验。
要点
- 多数研究将omPC定义为≤5个转移灶,但定义随影像技术和病灶数目/位置而变。
- omPC流行病学数据有限;同时性较异时性omPC的死亡率和总生存倾向更差。
- 无进展生存一般同时性较异时性omPC更长,但长时点更接近;治疗模式异质致结局多样。
核心结论
- omPC的定义取决于所用影像技术;流行病学数据稀缺;同时性与异时性队列生存率不同,治疗模式异质导致结局多样;需开展采用现代影像技术的临床试验。
研究设计与样本
- 针对性文献综述:检索MEDLINE和Embase,并检索灰色文献(如ClinicalTrials.gov)以寻找在研试验,共纳入105篇出版物。
主要发现
- omPC定义在出版物和omPC亚型间随转移灶数目、位置、影像类型和寡转移性疾病类型而异,多数研究定义为≤5个转移灶。
- omPC流行病学数据有限。
- 同时性较异时性omPC队列的死亡率和总生存倾向更差。
- 无进展生存一般同时性较异时性omPC队列更长,但在较长时点更接近。
- 综述还总结了在研的针对omPC男性的局部治疗、转移灶导向治疗和全身治疗临床试验。
局限性
- omPC流行病学数据有限。
- omPC定义因所用影像技术而异。
- 治疗模式异质导致结局多样。
- 需开展采用现代影像技术的临床试验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Prostate cancer is the most common noncutaneous malignancy among men in the USA and Europe. There is no consensus definition of oligometastatic prostate cancer (omPC), which is often considered in two subgroups, synchronous (de novo) and metachronous (oligorecurrent), and may include patients with a low metastatic disease burden. OBJECTIVE: To summarize the epidemiology, disease definitions, mortality/survival outcomes, and treatment characteristics in both clinical trial and real-world settings among patients with synchronous, metachronous, and mixed-subtype (ie, synchronous and metachronous or undefined type) omPC, as well as low burden disease states. EVIDENCE ACQUISITION: We searched MEDLINE and Embase to identify publications reporting on epidemiology, disease definitions, clinical outcomes, and treatment characteristics of omPC. Gray literature sources (eg, ClinicalTrials.gov) were searched for ongoing trials. EVIDENCE SYNTHESIS: We identified 105 publications. Disease definitions varied across publications and omPC subtypes on the number and location of lesions, type of imaging used, and type of oligometastatic disease. Most studies defined omPC as five or fewer metastatic lesions. Data on the epidemiology of omPC were limited. Mortality rates and overall survival tended to be worse among synchronous versus metachronous omPC cohorts. Progression-free survival was generally longer among synchronous than among metachronous omPC cohorts but was more similar at longer time points. A summary of ongoing clinical trials investigating a variety of local, metastasis-directed, and systemic therapies in men with omPC is also provided. CONCLUSIONS: Definitions of oligometastatic disease depend on the imaging technique used. Epidemiologic data for omPC are scarce. Survival rates differ between synchronous and metachronous cohorts, and heterogeneous treatment patterns result in varied outcomes. Ongoing clinical trials using modern imaging techniques are awaited and needed. PATIENT SUMMARY: Definitions of oligometastatic prostate cancer (omPC) vary depending on the imaging technique used. Different treatment patterns lead to different outcomes. Robust omPC epidemiologic data are lacking.
引用
- Antonarakis ES, Shui IM, Zaidi O, et al. Current Treatment Paradigms and Clinical Outcomes in Oligometastatic Prostate Cancer Patients: A Targeted Literature Review. Eur Urol Oncol. 2024. PMID: 38964996. doi:10.1016/j.euo.2024.06.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。